Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

Presentation TCT 2025

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

Presenter: Ahmed A. Mahmoud

October 28, 2025

Presentation TCT 2025

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

TCT 801: Comparative Efficacy and Safety of Beta Blockers Versus SGLT2 Inhibitors in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA)

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 760: SGLT2 Inhibitors Reduce Acute Kidney Injury and Improve Survival in Diabetic Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Priyesh Thakurathi

October 27, 2025

Presentation TCT 2025

TCT 755: Impact of SGLT2 Inhibitors on Outcomes After TAVR: A Real-World Propensity-Matched Analysis

Presenter: Salman Zahid

October 27, 2025

Presentation TCT 2025

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

Presentation TCT 2025

TCT 749: Renal Protective Effects of SGLT2 Inhibitors After Transcatheter Mitral Valve Repair in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Retrospective Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

HF Risks Stick Around Even When Ejection Fraction Improves

News Daily News

HF Risks Stick Around Even When Ejection Fraction Improves

August 01, 2025

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza

News Daily News

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza

July 25, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

Presentation NY Valves 2025

Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Tamari Lomaia

June 26, 2025

TCTMD’s Top 10 Most Popular Stories for May 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2025

May 30, 2025

TITRATE-HF: Use of GDMT for HF Is Getting Better but Still Not Ideal

News Conference News ESC Heart Failure 2025

TITRATE-HF: Use of GDMT for HF Is Getting Better but Still Not Ideal

May 21, 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

News Conference News ESC Heart Failure 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

May 20, 2025

Benefits of SGLT2 Inhibitors for HF Affirmed in Large, Real-world Study

News Daily News

Benefits of SGLT2 Inhibitors for HF Affirmed in Large, Real-world Study

May 09, 2025

STRONG-HF Analysis Quantifies Gains From Rapid Uptake of GDMT

News Daily News

STRONG-HF Analysis Quantifies Gains From Rapid Uptake of GDMT

May 08, 2025

BIO-LIBRA: Outcomes Vary by Sex, Device in Cardiomyopathy Patients With ICDs

News Conference News HRS 2025

BIO-LIBRA: Outcomes Vary by Sex, Device in Cardiomyopathy Patients With ICDs

May 02, 2025

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.